dor biopharma - 500 Beiträge pro Seite

[taipan11]

nun wird es vermutlich nicht mehr lange dauern, bis wir endlich wissen, ob orBec nun die zulassung von der fda erhalten wird.
der zulassungsantrag wurde am 22.09.2006 eingereicht.
die marktzulassung könnte dann vermutlich noch ende 2007 oder anfang 2008 erfolgen und würde dann endlich geld in die kassa spühlen.
was meint ihr dazu?

[schlobb]

Antwort auf Beitrag Nr.: 25.548.261 von taipan11 am 20.11.06 16:14:31

Ha - heute 40% eingebrochen --- dass nenn ich doch die richtige Zeit zum Nachkaufen!!!!

Und im Juni gint s die Zulassung.... dann geht s rund in der Kiste.
Gruesse, s.

[schlobb]

Antwort auf Beitrag Nr.: 29.192.203 von schlobb am 07.05.07 17:54:02

DOR Biopharma bei 0.32 in Frankfurt. Absoluter KAUFTIPP!!!!! 100% locker an einem Tag!!!

[schlobb]

News:

29-May-2007

Change in Directors or Principal Officers


Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On May 28, 2007, Steven H. Kanzer resigned as a member of the Company's board of directors (the "Board"). Mr. Kanzer was Vice-Chairman of the Board and a member of the audit, compensation and nominating committees of the Board. A copy of Mr. Kanzer's letter of resignation is filed herewith as Exhibit 99.1.

[schlobb]

Und weiter Richtung Norden....

hier ein paar News:

Fifty Companies Representing Twenty Industries Set to Present At the RedChip Small-Cap New York Investor Conference:

http://biz.yahoo.com/pz/070620/121685.html

das Ziel sond $2 bis 02/07.

Gruss - schlobb

[schlobb]

Mehr news:

No buy out!!!!

DOR BioPharma Adopts Shareholder Rights Plan

http://biz.yahoo.com/iw/070622/0269829.html

die Rakete startet!!!

[schlobb]

More news - Nur zu Info: Mr. Buhrman war mit der Praesentation vor der FDA durck Mr. Kanzer sehr unzufieden und hat sowohl Kanzer abgesetzt und jetzt seinen Platz im Direktorium eingefordert.

Bin mir sicher wir sehen hier einen starken Kursanstieg in den naechsten 6 Mon!!!

s.

DOR Appoints Cyrille F. Buhrman to Its Board of Directors
Friday June 29, 8:00 am ET

MIAMI, FL--(MARKET WIRE)--Jun 29, 2007 -- DOR BioPharma, Inc. (OTC BBORB.OB - News) ("DOR" or the "Company"), a biopharmaceutical company addressing life-threatening side effects of cancer and cancer treatments, serious gastrointestinal diseases and disorders, and biodefense countermeasures, today announced the appointment of Cyrille F. Buhrman to its board of directors.
ADVERTISEMENT

Mr. Buhrman is Managing Director, Chairman and owner of Pacific Healthcare (Thailand) Co., Ltd., a full service marketing, sales, distribution and regulatory affairs company based in Thailand where he has served for approximately ten years. Pacific Healthcare is currently expanding throughout Southeast Asia, starting with the Philippines and Vietnam this year. Mr. Buhrman is a Director of Pacific Healthcare (Philippines) Inc., International Pharmaceuticals Ltd., a company focused on marketing Specialty pharmaceutical products in Thailand, Vision Care (Thailand) Co., Ltd, and Canyon Pharmaceuticals, Inc., a private biotechnology company focused on the commercialization of therapeutics to prevent and treat thrombosis and related conditions. Mr. Buhrman is owner of Markle Holdings Ltd., an investment fund specializing in biotech and pharmaceutical investments. Mr. Buhrman is also one of DOR's largest shareholders.

"It is a pleasure to welcome Cyrille Buhrman to our board of directors," stated Christopher J. Schaber, DOR's President and Chief Executive Officer. "Mr. Buhrman's deep and diverse experience leading healthcare businesses and building commercial operations will be invaluable, particularly to the commercial growth of our orBec® franchise. We look forward to his keen insights and global business perspectives as we welcome him to our Board."

[schlobb]

Mehr news: Neben orBec auch eine Impfung gegen Botulinum Vergiftung in der Pipeline. Mein Tipp - strong buy!!!
schlobb wuenscht einen gruenen Tag.

Press Release Source: DOR BioPharma, Inc.

DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC(TM)
Monday July 2, 6:30 am ET

MIAMI, FL--(MARKET WIRE)--Jul 2, 2007 -- DOR BioPharma, Inc. (OTC BBORB.OB - News) ("DOR" or the "Company") announced today that the first results from testing of a multivalent form of its botulinum toxin vaccine, BT-VACC(TM), have been published in the journal Infection and Immunity (Ravichandran et al., 2007, Infection and Immunity, v. 75, p. 3043 ). These results are the first that describe the protective immunity elicited by a multivalent vaccine that is active by the mucosal route. The vaccine consists of a combination of three non-toxic subunits of botulinum toxin that induced protection against the corresponding versions of the natural toxins.
ADVERTISEMENT

The results published in Infection and Immunity show that non-toxic subunits (protein components of the natural toxin) of three of the serotypes of botulinum toxin that cause almost all instances of human disease, namely serotypes A, B, and E, can be combined and delivered via nasal administration. The combination vaccine induced antibodies in the serum of mice and protected against subsequent exposure to high doses of a combination of the natural A, B, and E serotype neurotoxins. Further, the combination vaccine can induce protection when given mucosally as a booster to animals that have been given a primary vaccine injection.

BT-VACC(TM) is composed of a component of what is known as the heavy chain of each of the A, B, and E serotypes. These components lack the region of the toxin that are responsible for blocking neurotransmitter functions. The subunits can bind avidly to receptors on the surface of mucosal cells and traverse lung and gastrointestinal tissue to stimulate immunity. Because the binding subunits lack the toxic part of the molecule, the vaccine is safe and stimulates antibodies in not only the blood but those antibodies that coat mucosal surfaces. It is thought that antibodies that are present in lung and gastrointestinal secretions will block the uptake of the toxin before entering the bloodstream and reaching peripheral nerves. BT-VACC(TM) originated from the work of Lance Simpson, PhD, and has been exclusively licensed from Jefferson Medical College.

"These results are a major step forward and represent the first demonstration of a multivalent vaccine that is active by the mucosal route," said Christopher J. Schaber, PhD, President and CEO of DOR. "We think that these results in animals demonstrate the potential of developing subunit vaccines that can be given by a mucosal route, avoiding the use of needles and injections, with greater ease of administration and convenience for the provider and the patient. Such vaccines would further have the advantage to stimulate antibodies that block absorption of toxin into the body. We expect that the successful development of a multivalent oral botulinum toxin vaccine that can be applied to rapidly deployable mass immunization programs will be a major step forward in Biodefense countermeasures."

"These results are valuable for two reasons," added Lance L. Simpson, PhD, Professor of Medicine and Director of the Center for Research on Bioterrorism and Biodefense at Jefferson Medical College. "First, they are a clear demonstration that it is feasible to create an inhalation or intranasal vaccine against the three botulinum serotypes that are of greatest concern to human health. Second, and looking toward the future, the results are a promising indicator that it should be possible to create an oral vaccine. There is a consensus among immunologists and public health officials that oral vaccination is one of the most desirable ways to protect vulnerable populations against toxic substances."

Because the toxin naturally enters lung and intestinal tissues very efficiently, it is specifically possible to engineer a botulinum vaccine that can be administered orally or via nasal administration. Unpublished results have also shown that oral administration of one of the serotype to rats results in significant levels of circulating antibodies as well as protection against toxin exposure.

[Bachelor2009]

die news haben sich ja super auf den kurs eingewirkt!!!!???

-7%

wie soll es da wohl weitergehen?